ÖZEN, H. Et Al. 2021. EFFICACY AND SAFETY OUTCOMES WITH ODEVIXIBAT IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS DUE TO DEFICIENCIES IN MULTIDRUG RESISTANCE PROTEIN 3 (PFIC TYPE 3) OR MYOSIN 5B (PFIC TYPE 6). HEPATOLOGY , vol.74 .

ÖZEN, H., Sokal, E., Lacaille, F., DALGIÇ, B., Ni, Q., Kjems, L., ... Horn, P.(2021). EFFICACY AND SAFETY OUTCOMES WITH ODEVIXIBAT IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS DUE TO DEFICIENCIES IN MULTIDRUG RESISTANCE PROTEIN 3 (PFIC TYPE 3) OR MYOSIN 5B (PFIC TYPE 6). HEPATOLOGY , vol.74.

ÖZEN, HASAN Et Al. "EFFICACY AND SAFETY OUTCOMES WITH ODEVIXIBAT IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS DUE TO DEFICIENCIES IN MULTIDRUG RESISTANCE PROTEIN 3 (PFIC TYPE 3) OR MYOSIN 5B (PFIC TYPE 6)," HEPATOLOGY , vol.74, 2021

ÖZEN, HASAN Et Al. "EFFICACY AND SAFETY OUTCOMES WITH ODEVIXIBAT IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS DUE TO DEFICIENCIES IN MULTIDRUG RESISTANCE PROTEIN 3 (PFIC TYPE 3) OR MYOSIN 5B (PFIC TYPE 6)." HEPATOLOGY , vol.74, 2021

ÖZEN, H. Et Al. (2021) . "EFFICACY AND SAFETY OUTCOMES WITH ODEVIXIBAT IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS DUE TO DEFICIENCIES IN MULTIDRUG RESISTANCE PROTEIN 3 (PFIC TYPE 3) OR MYOSIN 5B (PFIC TYPE 6)." HEPATOLOGY , vol.74.

@article{article, author={HASAN ÖZEN Et Al. }, title={EFFICACY AND SAFETY OUTCOMES WITH ODEVIXIBAT IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS DUE TO DEFICIENCIES IN MULTIDRUG RESISTANCE PROTEIN 3 (PFIC TYPE 3) OR MYOSIN 5B (PFIC TYPE 6)}, journal={HEPATOLOGY}, year=2021}